Compare KraneShares CSI China Internet ETF (KWEB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Mesoblast Limited — how do they compare? KraneShares CSI China Internet ETF trades at $24.93 (market cap $4.37B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: KraneShares CSI China Internet ETF is far larger — about 2.5× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 13,393,361). Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Mesoblast Limited for 15 Days on average.
| KWEB | MESO | |
|---|---|---|
Market Cap | $4.37B | $1.75B |
Volume | 13,393,361 | 239,027 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $20.96 |
52-Week Low | $23.63 | $13.19 |
Typical Hold Time | 57 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $24.025, down 1.25% amid bearish technical signals with all 13 moving averages indicating sell pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption, though recent institutional activity shows mixed positioning with some firms reducing stakes while others increase exposure ahead of potential trade developments.
The outlook remains cautious given China's macroeconomic pressures and ongoing U.S.-China trade tensions, though corporate profits surged 26% in Q2 2026. Key risks include global protectionism against Chinese exports and regulatory uncertainty, while potential trade agreement progress could provide catalysts for the battered Chinese internet sector.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
